Provided by Tiger Trade Technology Pte. Ltd.

Innoviva

20.66
+0.04000.19%
Post-market: 20.660.00000.00%19:30 EDT
Volume:727.35K
Turnover:14.98M
Market Cap:1.49B
PE:4.80
High:20.88
Open:20.84
Low:20.45
Close:20.62
52wk High:25.15
52wk Low:16.52
Shares:72.25M
Float Shares:69.02M
Volume Ratio:1.00
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.30
EPS(LYR):3.30
ROE:36.68%
ROA:6.95%
PB:1.21
PE(LYR):6.26

Loading ...

Innoviva names Josephine Linden to board after Small, DiPaolo resign

Reuters
·
May 19

Armata Q1 FY26 net loss widens to $115.35 million

Reuters
·
May 14

Innoviva management to meet with BTIG

TIPRANKS
·
May 14

Innoviva (INVA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 07

Innoviva Is Maintained at Buy by BTIG

Dow Jones
·
May 07

Innoviva reports Q1 EPS $2.22 vs (74c) last year

TIPRANKS
·
May 07

Innoviva Q1 EPS $2.22 Beats $0.36 Estimate, Sales $97.994M Miss $101.555M Estimate

Benzinga Earnings
·
May 07

Innoviva swings to Q1 FY26 net income USD 186.6 million; revenue rises 11% to USD 98 million

Reuters
·
May 07

BRIEF-Innoviva Q1 Royalty Revenue USD 55.167 Million

Reuters
·
May 07

A Look At Innoviva (INVA) Valuation After Shelf Registration For Potential US$208 Million Stock Offering

Simply Wall St.
·
May 05

Innoviva Shareholders Back Directors, Pay Plan and Incentives

TIPRANKS
·
May 05

Innoviva shareholders approve 2026 equity incentive plan at annual meeting

Reuters
·
May 05

Armata reports cryo-EM study maps structure of Pseudomonas phage P7-1

Reuters
·
May 04

Armata Pharma director Daniel Gilmer files initial beneficial ownership statement

Reuters
·
Apr 29

Armata Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 28

Armata Pharmaceuticals FY2025 net loss more than doubled to $174 million; revenue slips 5.22% to $4.9 million

Reuters
·
Mar 26

Innoviva Announces Annual Stockholder Meeting

Reuters
·
Mar 25

Basilea Pharmaceutica AG publishes investor presentation on anti-infective portfolio and pipeline development

Reuters
·
Mar 23

Armata Pharmaceuticals delays Q4 and full-year 2025 results announcement

Reuters
·
Mar 19